Results 51 to 60 of about 16,441 (147)

The role of factor Xa inhibitors in venous thromboembolism treatment

Vascular Health and Risk Management, 2015
Katherine P Cabral,1 Jack E Ansell2 1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Hofstra-North Shore/LIJ School of Medicine, Hempstead, NY, USA Abstract: Three factor Xa inhibitors have been studied
Cabral KP, Ansell JE
doaj  

Urine-based point-of-care testing for factor-Xa-inhibitors in acute ischemic stroke patients: a feasibility study. [PDF]

Front Neurol, 2023
Doeppner TR, Olbricht L, Maxhuni T, Alhaj Omar O, Sachs UJ, Juenemann MB, Huttner HB, Gerner ST.   +7 more
europepmc   +1 more source

Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations

Journal of Blood Medicine, 2014
Ingo Ahrens, Christoph Bode Heart Center, University of Freiburg, Department of Cardiology and Angiology I, Freiburg, Germany Abstract: The direct factor Xa inhibitor rivaroxaban was the first within the group of orally available direct factor Xa ...
Ahrens I, Bode C
doaj  

Residue‑resolved dynamically averaged interaction analysis of direct factor Xa inhibitors by MD‑FMO combination calculations. [PDF]

J Comput Aided Mol Des
Yoshine R, Hirano Y, Doi H, Kitahara S, Akisawa K, Okuwaki K, Yamamoto E, Yasuoka K, Mochizuki Y.   +8 more
europepmc   +1 more source

The 5 most frequently asked questions about factor Xa inhibitors. [PDF]

Hematology Am Soc Hematol Educ Program, 2022
Wang TF, Carrier M.
europepmc   +1 more source

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism. [PDF]

Cochrane Database Syst Rev, 2023
Li M, Li J, Wang X, Hui X, Wang Q, Xie S, Yan P, Tian J, Li J, Xie P, Yang K, Yao L.   +11 more
europepmc   +1 more source

The impact of body composition variability on coagulation monitoring in patients on direct oral factor Xa inhibitors for treatment of venous thromboembolism. [PDF]

Front Cardiovasc Med
Kurzmann-Guetl K, Leitner DR, Gary T, Avian A, Beck A, Rabensteiner J, Prueller F, Raggam RB, Brodmann M, Toplak H.   +9 more
europepmc   +1 more source

Incomplete harms reporting in systematic reviews of direct oral factor Xa inhibitors. [PDF]

Blood Adv
Rea J, Lee C, Kee M, Rucker B, Flores H, Walters C, Haney T, Tomlin A, Khan A, Vassar M.   +9 more
europepmc   +1 more source

Position statement of the Polish Society of Gastroenterology on the use of andexanet alfa in patients with gastrointestinal bleeding taking factor Xa inhibitors. [PDF]

Prz Gastroenterol
Adrych K, Daniluk J, Nowakowska-Duława E, Białek A, Rydzewska GM.   +4 more
europepmc   +1 more source

Peak and Trough Concentration Ranges of Factor Xa Inhibitors for Preventing Thromboembolic Stroke in Korean Patients with Non-valvular Atrial Fibrillation. [PDF]

Ann Lab Med
Park JS, Lim KH, Kim DH, Lee KM, Woo KS, Han JY.   +5 more
europepmc   +1 more source